Jason Hyatt

Jason has advised issuers, underwriters, and other market participants on transactions in the U.S. and EMEA equity and debt capital markets including:
Equity Offerings:

• The underwriters in connection with the upsized, underwritten public offering of ordinary shares of a leading global provider of drug containment and delivery solutions for the pharmaceutical, biotechnology, and life science industries.
• A clinical-stage biopharmaceutical company in connection with the establishment of an at-the-market equity program.
• A Swedish-Swiss multinational electrical engineering corporation on U.S. law matters in connection with its spinoff and Switzerland’s principal stock exchange listing of its turbocharging business.
• A healthcare technology company in connection with its initial public offering.
•  The underwriters in connection with the initial public offering of shares of common stock of a clinical-stage targeted oncology company.
• A biopharmaceutical company in connection with its public offering of shares of common stock.
• An Ireland-based pharmaceutical company in connection with its public offering of ordinary shares (or pre-funded warrants in lieu thereof).
• The underwriters in connection with the public offering of shares of common stock by a clinical-stage biopharmaceutical company.
• A French, late-stage, clinical biotechnology company in connection with its initial public offering.
• An American advertising company in connection with its $400 million private placement of 400,000 shares of Series A Convertible Perpetual Preferred Stock.
• A French biopharmaceutical company in connection with its public offering of American Depositary Shares.
• A biotechnology company in connection with its public follow-on offering of common stock.

SPAC Transactions:

• A global digital operator and its digital operator in Ukraine in connection with the execution of a business combination agreement with a SPAC.
• A private equity firm and a leading supplier of copper specialty products in connection with its execution of a business combination agreement with a SPAC.
• Represented 10X Capital in connection with its de-SPAC transaction with a global food security company operating a commercial-scale alfalfa farm on the African continent.
• Represented 10X Capital in connection with its business combination agreement with a clinical-stage, HIV-focused, gene therapy company.
• Represented 10X Capital in connection with its business combination agreement with a diversified infrastructure provider and blockchain technology company.

Debt Offerings:

• An American global financial services and bank holding company in its $850 million, registered, senior subordinated notes offering.
• A leading manufacturer and distributor of packaging and tissue products in connection with the issuance of US$300 million in aggregate principal amount of senior notes in a Rule 144A and Regulation S offering, as well as a tender offer for any and all outstanding principal amounts of US$200 million senior notes.
• An American advertising company in connection with issuances of senior notes in Rule 144A and Regulation S offerings.
• The underwriters in connection with several public note offerings by a leading food and beverage company.

The above matters were handled by Jason prior to joining Sidley.